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INTRODUCTION
Cardiovascular disease (CVD) is a
leading cause of mortality and morbidity
throughout the world (1–3). Most of the
clinical manifestations of CVD (for exam-
ple, myocardial infarction [MI], stroke
and peripheral vascular disease) are
caused by atherosclerosis (2). Subclinical
atherosclerosis begins with subendothe-
lial retention of lipoproteins and thicken-
ing of the arterial intima layer that may
subsequently develop into atheroscle-
rotic plaques (4,5). There is ample evi-
dence that atherosclerosis is an inflam-
matory disease (1–3,6). The vessel wall is
progressively infiltrated by leukocytes,
lipids and debris, which contribute to
plaque development and plaque inflam-
mation, promote plaque instability and
increase the risk for plaque rupture and
clinical disease (1–3,6).
T cells are central orchestrators of the
chronic inflammatory activity in athero-
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sclerotic plaques. Both effector T cells
(TEFF) and regulatory T cells (TREG) are in-
volved in the control of inflammatory ac-
tivity and lesion development. Low lev-
els of TREG have been associated with
increased risk for MI (7), and depletion
of TREG promotes increased experimental
atherosclerosis and dyslipidemia (8).
Conversely, depletion of the TEFF popula-
tion reduces atherosclerosis development
(9,10).
T cells require two signals for activa-
tion: a signal from the T-cell receptor
upon antigen recognition and an addi-
tional signal from a costimulatory recep-
tor. The tumor necrosis factor receptor
superfamily member 9 (TNFRSF9),
CD137, is a costimulatory receptor of the
TREG as well as TEFF subtypes of T cells
(11,12). CD137 plays a key role in activa-
tion of the proinflammatory
CD4+CD28null T cells, a subpopulation
that is increased in patients with acute
coronary syndrome (ACS) compared
with patients with stable angina or con-
trols. This result suggests a role of in-
creased CD137 activation in ACS (13).
We have previously shown that CD137
is expressed in both human and murine
atherosclerotic lesions. Stimulation of
CD137 in a murine model of atheroscle-
rosis promotes atherosclerotic disease,
with increased lesion size, increased
local inflammatory activity and in-
creased plaque infiltration of T cells (14).
Conversely, CD137 deficiency reduces
atherosclerosis in Apoe–/– and Ldlr–/–
mice (15). Thus, CD137 plays a signifi-
cant role in murine atherogenesis, but
CD137 in human atherosclerosis is not
well understood.
Efforts to develop agents that target
human CD137 are underway (11,16,17).
Because CD137 signaling influences ex-
perimental atherosclerosis, and knowl-
edge on CD137 in human CVD is lim-
ited, intervention in CD137 signaling in
human atherosclerosis is at present un-
warranted. To gain further information
about CD137 in human atherosclerosis,
on the basis of our previous published
experimental data and knowledge of the
effects of CD137 activation on atheroscle-
rosis (14), we hypothesized that genetic
variants in CD137 influence CD137 ex-
pression and atherosclerotic disease. To
study CD137 in atherosclerosis, we used
a genetic approach of mRNA expression
in lymphoblastoid cell lines together
with population-based cohorts with a
high prevalence of cardiovascular risk
factors.
MATERIALS AND METHODS
Selection of Genetic Variants in CD137
Publicly available data on genotype
from the HapMap CEU population (18)
and gene expression from lymphoblas-
toid cell lines derived from the same
population (19) were used to investigate
association of genotype with gene ex-
pression. The 42 single nucleotide poly-
morphisms (SNPs) in CD137 were identi-
fied in HapMap (HapMap Data Freeze
#21a, http://hapmap.ncbi.nlm.nih.gov)
(18). CD137 mRNA expression was in-
vestigated by using the Affymetrix
GeneChip Human Exon 1.0 ST Array
data accessible through the GEO Series
accession number GSE9372, as previ-
ously described (19).
Measurement of Carotid 
Intima-Media Thickness (IMT)
Association of genotype and subclini-
cal atherosclerosis, measured as intima-
media thickness (IMT) in the carotid
 arteries and determined by ultrasonogra-
phy, was studied in a cohort of 3,430 par-
ticipants in the IMPROVE study (20,21).
In short, the IMPROVE study is a multi-
center study that enrolled 54- to 79-year-
old men and women with at least three
risk factors for CVD in Finland, France,
Italy, the Netherlands and Sweden. Risk
factors were as follows: male sex or 
≥5 years after menopause for women;
dyslipidemia, defined as hypercholester-
olemia (mean calculated low-density
lipoprotein [LDL] cholesterol levels 
>160 mg/dL or treatment with lipid-
 lowering drugs); hypertriglyceridemia
(triglyceride levels >200 mg/dL or treat-
ment with triglyceride-lowering drugs);
hypoalphalipoproteinemia (high-density
lipoprotein [HDL] cholesterol <40 mg/dL);
hypertension (defined as diastolic blood
pressure >90 mmHg and/or systolic blood
pressure >140 mmHg or treatment with
antihypertensive drugs); diabetes (defined
as fasting glucose level >126 mg/dL
[7.0 mmol/L] or treatment with insulin or
oral hypoglycemic drugs); smoking; or
family history of CVD. Participants were
free of symptomatic CVD and any condi-
tions that might limit longevity, for exam-
ple, cancer, at the time of enrollment. All
subjects were included after written con-
sent. The carotid IMT was measured
using B-mode ultrasound, and clinical
and biochemical data were collected as
previously described (20). In brief, the far
walls of both the left and right carotid ar-
teries were examined at two levels of the
common carotid: the bifurcation and the
internal carotid arteries.
Ultrasonography was performed from
the anterior, lateral and posterior views
and recorded on S-VHS. IMT measure-
ments were carried out by a centralized
laboratory, and repeatability was moni-
tored as described (20). The variables
measured were the mean and maximum
IMT of the common carotid at the first
centimeter (cm) proximal to the bifurca-
tion (CC-first cm-IMTmean and CC-first
cm-IMTmax) and in a segment excluding
the first centimeter proximal to the bifur-
cation (CC-IMTmean and CC-IMTmax) and
of the bifurcation (Bif-IMTmean and Bif-
IMTmax) and of the internal carotid arter-
ies (ICA-IMTmean and ICA-IMTmax). Com-
posite IMT variables considering the
whole carotid tree were derived from the
segment-specific measurements: IMTmean,
IMTmax and IMTmean-max (the average of
maximal IMT recorded at the different
segments). Presence of plaque in a seg-
ment was defined as IMTmax >1.5 mm.
IMT determinations were repeated at 15
and 30 months of follow-up. Thirty-
month progression of all IMT measure-
ments (IMTmax progression, change over
time, in mm/year) was calculated by lin-
ear regression considering all three time
points (0, 15 and 30 months). Results in
the present study were analyzed by three
models: (a) a basic model adjusting for
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sex, age and genetic background (multi-
ple dimension scaling [MDS]), (b) a
model including also the identified con-
founders (hypercholesterolemia, hyper-
triglyceridemia and current smoking)
and (c) a model including all established
risk factors listed in Table 1, except the
three variables describing family history
of vascular disease, because of a high de-
gree of missing data. Subjects were fol-
lowed up with respect to incident vascu-
lar events (coronary, cerebral or
peripheral) until 36 months (20).
rs2453021 and Incident Vascular
Events
Association of rs2453021 with clinical
outcome was analyzed by using pro-
spective data collected during the 36-
month follow-up of the IMPROVE co-
hort (20). Vascular events were analyzed
by Cox regression as (a) any vascular
event, (b) cardiac events only, (c) non-
cardiac events (cerebral or peripheral),
(d) cerebral vascular events only and 
(e) peripheral vascular events only.
Analyses were performed using the
same three models as for the IMT meas-
urements. Genotyping of rs2453021 in
IMPROVE was performed by using 
Illumina GoldenGate technology at 
the SNP&SEQ Technology Platform
(Uppsala, Sweden).
rs2453021 and Coronary Artery
Disease
Association of rs2453021 with coronary
artery disease (CAD) was analyzed in
5,765 CAD and/or MI cases from the
PROCARDIS project (22), along with
Table 1. Subject characteristics and risk factor prevalence according to the rs2453021 genotype in IMPROVE.
Genotype
CC CT TT P
n 1,517 1,510 391
Subject characteristics
Male sex (%) 48.4 47.9 48.3 0.888
Age (years) [mean (95% CI)] 64.4 (64.2–64.7) 64.0 (63.8–64.3) 64.1 (63.6–64.7) 0.091
BMI (kg/m2) [mean (95% CI)] 27.2 (27.0–27.4) 27.3 (27.1–27.5) 27.1 (26.7–27.5) 0.859
CRP (mg/L) [median (IQR)] 1.86 (0.74–3.67) 1.86 (0.78–3.53) 1.86 (0.80–3.58) 0.719
Risk factors
Hypercholesterolemia (%) 68.3 69.7 76.2 0.008
Hypertriglyceridemia (%) 23.7 28.2 27.6 0.012
Hypoalphalipoproteinemia (%) 12.5 13.7 14.1 0.308
Hypertension (%) 70.6 67.3 68.3 0.122
Diabetes (%) 27.9 26.1 24.2 0.114
Family history of peripheral vascular disease (%)
No 79.5 77.4 81.3 0.435
Yes 11.0 13.2 11.0
Not known 9.6 9.4 7.7
Family history of cerebrovascular disease (%)
No 60.3 61.2 59.8 0.902
Yes 35.2 35.3 36.1
Not known 4.6 3.6 4.1
Family history of coronary heart disease (%)
No 32.9 35.1 34.3 0.389
Yes 63.2 61.6 62.4
Not known 3.8 3.2 3.3
Current smoker (%) 16 15.2 9.5 0.006
Smoking pack-year category (%)
Never smoker 48.4 49.6 50.4 0.234
1st quartile 12.3 12.3 14.9
2nd quartile 13.8 11.9 12.1
3rd quartile 11.9 13.4 10.8
4th quartile 13.6 12.9 11.8
P values are from linear regression and χ2 tests for linear-by-linear association. Dyslipidemia was defined as hypercholesterolemia (mean
calculated LDL cholesterol levels >160 mg/dL or treatment with lipid-lowering drugs), hypertriglyceridemia (triglyceride levels >200 mg/dL
or treatment with triglyceride-lowering drugs) and hypoalphalipoproteinemia (HDL cholesterol <40 mg/dL). Hypertension was defined as
diastolic blood pressure >90 mmHg and/or systolic blood pressure >140 mmHg or treatment with antihypertensive drugs. Diabetes was
defined as fasting glucose level >126 mg/dL (7.0 mmol/L) or treatment with insulin or oral hypoglycemic drugs (20). IQR, interquartile
range. Genotype: CC, homozygote major C allele; CT, heterozygote; TT, homozygote minor T allele.
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7,264 controls from PROCARDIS and the
Wellcome Trust Case Control Consor-
tium (WTCCC) (23); in total, 13,029 indi-
viduals were analyzed using imputed
genotype data. Briefly, PROCARDIS is a
multicenter European project that assem-
bled a uniquely large and carefully phe-
notyped cohort of subjects with CAD
with onset of MI or other ACS before 65
years of age. All PROCARDIS partici-
pants included in the present study had
been genotyped by using either the Illu-
mina Human 1M or 610K quad arrays
and imputed to 1,000 Genomes (CEU
panel August 2009 release) by using
MACH software (24).
Statistics
For expression quantitative trait locus
(eQTL) studies, the association was cal-
culated according to an additive linear
model. Briefly, genotypes were re-coded
as 1, 2 or 3 corresponding to homozygote
major allele, heterozygote or homozy-
gote minor allele. This value was fitted
to the TNFRSF9 (CD137) gene expression
in a linear regression model, and the
P value for the fit of the slope was calcu-
lated. All eQTL calculations were per-
formed in R version 2.9.2.
Associations of genotype with baseline
IMT and IMT progression were investi-
gated by linear regression assuming an
additive genetic effect, by using PLINK
version 1.07 (25). Cox regression analysis
of genotype associations with incident
vascular events and additional statistical
analyses were performed by using IBM
SPSS Statistics version 20 (IBM Corpora-
tion, Armonk, NY, USA). Analyses of
genotype associations with IMT and inci-
dent events were adjusted for sex, age
and genetic background (MDS compo-
nents 1–3 based on CardioMetabo-chip
data) (21) and, where indicated, for po-
tential confounders and additional co-
variates. Associations of genotype with
presence of plaque were investigated by
logistic regression by using the same ad-
justments. Because of non-normal distri-
bution, all baseline IMT variables and
C-reactive protein levels measured in
IMPROVE were logarithmically trans-
formed before statistical analysis.
Disease (CAD and MI)-SNP associa-
tion was tested by applying a logistic re-
gression model by using STATA/MP 11
(StataCorp LP, College Station, TX, USA).
Analyses were adjusted for age, sex,
country of origin and relatedness.
RESULTS
The Minor Allele of rs2453021 Was
Associated with Decreased CD137
mRNA Expression
We first set out to investigate associa-
tion between SNPs at the CD137 locus
and CD137 mRNA expression levels. To
study this, we combined two publicly
available databases: the genotyping proj-
ect of HapMap as well as an expression
analysis performed on cell lines from the
same population (18,19). Thus, we cre-
ated a new data set containing both
genotype and expression data. The
minor T allele of rs2453021 was associ-
ated with significantly lower CD137 ex-
pression (all individuals, β = 0.797, 95%
confidence interval [CI] 0.726–0.876, P =
4.0 × 10–6, n = 171; Figure 1). Although
there was overlap in the distributions 
of CD137 mRNA levels, the linear effect
of the rs2453021 genotype was highly sig-
nificant, as evidenced by the low P value.
There was a difference between sexes in
Figure 1. The minor T allele of rs2453021 was associated with lower CD137 mRNA expres-
sion. A combined data set of genotyping data from the HapMap CEU population to-
gether with gene expression data from transcriptomic analysis of lymphoblastoid cell lines
derived from the same population was created. rs2453021 genotype and CD137 mRNA
expression was analyzed in a linear regression model for (a) all individuals (β = 0.797, 95%
CI 0.726–0.876, P = 4.0 × 10–6), (b) in males only (β = 0.689, 95% CI 0.589–0.805, P = 7.8 ×
10–6) and (c) in females only (β = 0.894, 95% CI 0.799–1, P = 0.05). Values shown are log2
CD137 mRNA expression. P values were calculated for fit of slope. For all, n = 171; males, 
n = 87; and females, n = 84. Genotype: CC, homozygote major C allele; CT, heterozygote;
TT, homozygote minor T allele.
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that the minor T allele was associated
with lower CD137 expression in males,
but this comparison of CD137 expres-
sion only reached borderline signifi-
cance in females (β = 0.689, 95% CI
0.589–0.805, P = 7.8 × 10–6, n = 87, versus
β = 0.894, 95% CI 0.799–1, P = 0.050, 
n = 84) (Figure 1). There was a signifi-
cant interaction of sex and genotype and
expression level of CD137 (P = 0.007).
There was no association between other
investigated CD137 SNPs and CD137
mRNA expression (data not shown). Ac-
cordingly, rs2453021 was selected for
further studies.
The Minor T Allele of rs2453021 Was
Associated with Increased IMT and
Presence of Plaque in the Common
Carotid Artery
We then turned to the IMPROVE co-
hort to investigate whether rs2453021
genotype was associated with carotid
IMT at baseline or at 30 months of pro-
gression of carotid IMT, as determined
by high-resolution ultrasound. Basic
characteristics and prevalence of estab-
lished cardiovascular risk factors of the
subjects in this study are presented in
Table 1. Genotype data passing quality
control were obtained for rs2453021 in
3,418 of 3,430 available subjects (call-rate
0.9965). We observed that the rs2453021
minor T allele (minor allele frequency
0.34) was associated with increased prev-
alence of hypercholesterolemia, hyper-
triglyceridemia and decreased preva-
lence of current smoking (Table 1).
Therefore, IMT associations were investi-
gated by three different models (Table 2):
(a) a basic model adjusting for sex, age
and genetic background (MDS), (b) a
model that also included the identified
confounders (hypercholesterolemia, hy-
pertriglyceridemia and current smoking)
and (c) a model that included all vari-
ables listed in Table 1, except the three
variables describing family history of pe-
ripheral, cerebrovascular and coronary
heart disease, as such information was
missing for many subjects.
The rs2453021 minor T allele was asso-
ciated with thicker CC-IMT indepen-
dently of vascular risk factors; the T al-
lele showed a significant positive
association with mean and maximum
IMT of the common carotid artery (CC-
IMTmean and CC-IMTmax) in all three
models at baseline (Table 2). The
rs2453021 T allele also showed a negative
association with the 30-month progres-
sion of the maximum IMT measured in
the whole carotid tree (IMTmax progres-
sion) in the first two models, but this as-
sociation disappeared after adjusting for
all vascular risk factors in model 3, indi-
cating that it may at least in part be due
to confounding factors (Table 2 and Fig-
ure 2). Among the additional covariates
in model 3, the loss of significance was
attributed mainly to diabetes; addition of
covariates one by one to model 2 showed
that further adjustment for diabetes had
the greatest impact (SNP-IMTmax progres-
sion association after addition of diabetes
to model 2: β = –0.0083, 95% CI
–0.0169–0.0004; P = 0.062). The preva-
lence of diabetes was positively associ-
ated with IMTmax progression (unad-
justed β = 0.0139, 95% CI 0.0009–0.0269;
P = 0.037). Taken together with the ten-
dency toward lower diabetes prevalence
for the T allele (Table 1), this result indi-
cates that the SNP-IMTmax progression
association seen in models 1 and 2, at
least in part, may be due to confounding
by diabetes status. No other significant
association with baseline IMT or IMT
progression at 30 months were observed
in any of the three models in analyses of
men and women together (data not
shown). Analyses performed in men and
women separately showed that the
Table 2. Association of rs2453021 with carotid IMT: baseline and 30-month progression.
Model 1 Model 2 Model 3
β (95% CI) n P β (95% CI) n P β (95% CI) n P
Baseline IMT
CC-IMTmean 0.0039 (0.0004–0.0074) 3,415 0.028 0.0045 (0.0011–0.0080) 3,411 0.010 0.0047 (0.0013–0.0082) 3,292 0.007
CC-IMTmax 0.0063 (0.0008–0.0119) 3,415 0.025 0.0070 (0.0015–0.0126) 3,411 0.013 0.0075 (0.0019–0.0131) 3,292 0.008
IMT progression
IMTmax prog –0.0091 (–0.0177 to 3,031 0.038 –0.0092 (–0.0178 to 3,028 0.037 –0.0077 (–0.0164 to 2,922 0.084
–0.0005) –0.0006) 0.0010)
The rs2453021 was associated with increased mean intima-media thickness (IMTmean) and maximum IMT (IMTmax) in the common carotid
(CC) artery in the IMPROVE cohort, independently of vascular risk factors. The rs2453021 was associated with decreased IMT progression
(IMTmaxprog) by using models 1 and 2, but this association was abolished when compensating for all risk factors using model 3 (see
below). Carotid artery atherosclerosis was evaluated in participants with at least three risk factors for CVD, but no clinical CVD at the
time of enrollment using high-resolution ultrasound at baseline and 30 months. Results are from linear regression analysis assuming an
additive genetic effect. Effect sizes (β) with 95% CIs for the rare T allele are shown. Model 1 is adjusted for sex, age and genetic
background (MDS); model 2 is adjusted for sex, age, genetic background (MDS) and variables in Table 1 found to be associated with
rs2453021 (hypercholesterolemia, hypertriglyceridemia, current smoking); and model 3 is adjusted for sex, age, genetic background
(MDS) and all variables in Table 1 (hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia, hypertension, diabetes,
current smoking, smoking pack-year categories, BMI and CRP), except the three variables describing family history of vascular disease,
due to a high degree of missing data. No other significant associations with baseline IMT or 30-month IMT progression were observed for
any of the three models (data not shown).
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minor T allele of rs2453021 was associ-
ated with higher CC-IMTmean in men but
not in women (model 3, P = 0.007 and 
P = 0.32, respectively), with slower 
IMTmax progression in men but not in
women (model 3, P = 0.01 and P = 0.95,
respectively) and with higher CC-IMTmax
in women but not in men (model 3, P =
0.02 and P = 0.11, respectively).
We then proceeded to analyze associa-
tion of rs2453021 with the presence of
plaque at baseline in all subjects. The
rs2453021 minor T allele was signifi-
cantly associated with presence of plaque
in the common carotid artery, using all
three models (CC-IMTmax >1.5 mm;
model 3 odds ratio 1.19, 95% CI
1.03–1.38, P = 0.02), but not with pres-
ence of plaque in any other carotid seg-
ment (not shown). No significant associ-
ation with the presence of plaque was
detected in any segment when men and
women were analyzed separately using
models 1–3; loss of significance with re-
spect to common carotid plaque pres-
ence was due to loss of statistical power,
since effect sizes (odds ratios) were pre-
served in both sexes (model 3 odds ra-
tios 1.23 [95% CI 0.97–1.57], P = 0.091 in
women, and 1.18 [0.97–1.42], P = 0.097
in men).
The Minor Allele of rs2453021 Was
Associated with Increased Risk of
Incident Noncardiac Vascular Events
To explore the association of the minor
T allele of rs2453021 with incident clini-
cal events, we analyzed prospective data
collected during the 36-month follow-up
of the IMPROVE cohort by Cox regres-
sion analysis, with adjustments accord-
ing to models 1–3. Among a total of 3,418
subjects, 190 subjects suffered at least one
event during a median follow-up of 36.2
months (interquartile range 35.8–37.4
months). The minor T allele of rs2453021
was significantly associated with in-
creased risk of noncardiac events using
model 3 (hazard ratio per rare T allele
1.42, 95% CI 1.02–1.98, P = 0.036; n = 74
subjects with events among 3,295 subjects
with nonmissing covariates [Table 3]).
There was no association between
rs2453021 and “cardiac events only” or
“any vascular event” or with peripheral
vascular or cerebrovascular events sepa-
rately, using model 3 (Table 3). In a sex-
stratified analysis using model 3, the
rs2453021 T allele was associated with
higher risk of peripheral events in men,
but not in women (P = 0.04 and P = 0.77,
respectively). No significant association
between the minor allele and risk for any
vascular events was observed using
models 1 and 2 (data not shown). Fur-
thermore, there was no detectable associ-
ation between rs243021 genotype and
Figure 2. The minor T allele of rs2453021 in CD137 was associated with increased intima-
media thickness (IMT) in the common carotid (CC) artery independently of vascular risk
factors. IMT was measured by high-resolution ultrasonography in the IMPROVE cohort. Par-
ticipants had at least three risk factors of CVD at the time of enrollment but were free of
clinical disease. Measurements were made at baseline and at 15 and 30 months. Thirty-
month progression of IMT (Prog CC-IMT) (change over time; in mm/year) was calculated
by linear regression considering all three time points (0, 15 and 30 months). Values are
mean CC-IMT (Mean CC-IMT; in mm) (A), maximum CC-IMT (Max CC-IMT; in mm) (B) and
maximum IMT progression (Prog Max IMT; in mm/year) (C) according to rs2453021 geno-
type. Results are adjusted for sex, age, cardiovascular risk factors (hypercholesterolemia,
hypertriglyceridemia, hypoalphalipoproteinemia, hypertension, diabetes, current smoking,
smoking pack-year categories, body mass index [BMI] and CRP) and genetic back-
ground (MDS) (model 3). The antilog of mean levels with 95% CI of logarithmically trans-
formed data are shown. Linear regression P values are indicated. Genotype: CC, homozy-
gote major C allele; CT, heterozygote; TT, homozygote minor T allele.
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levels of C-reactive protein (CRP) in
blood (Table 1).
The Minor Allele of rs2453021 Was Not
Associated with Increased Risk of
CAD in PROCARDIS/WTCCC
To investigate the association between
rs2453021 genotype and CAD or MI, we
turned to the combined PROCARDIS/
WTCCC case-control cohort (22,23). In
total, 13,029 individuals, including 5,765
cases and 7,264 controls, were investi-
gated. Basic clinical characteristics of
this sample have been reported (22).
There was no association between pres-
ence of the minor T allele of rs2453021
and risk for CAD or MI in this sample
(Table 4).
DISCUSSION
This preformed hypothesis-driven can-
didate gene study links rs2453021 to
CD137 expression levels and risk of
 atherosclerosis-related vascular events in
humans and thus provides the first ge-
netic evidence that suggests involvement
of CD137 in human atherosclerosis. The
minor T allele of rs2453021 was associ-
ated with lower CD137 mRNA expres-
sion in lymphoblastoid cells. Indepen-
dently of established vascular risk
factors, the minor T allele was also asso-
ciated with increased IMT and a higher
prevalence of IMT-defined plaque in the
CCA. Furthermore, the minor T allele
was associated with an increased risk of
clinical noncardiac (cerebrovascular or
peripheral) vascular events.
We and others have previously shown
that activation of CD137 has adverse ef-
fects on experimental atherosclerosis
(13–15,26). However, the impact of the
CD137 genotype on human atherosclero-
sis and clinical disease has not been in-
vestigated. This study uses genetic and
gene expression databases combined
with a CAD case-control study and a
prospective study of subjects with high
cardiovascular risk. 
Here, we show that the minor T allele
of rs2453021 was associated with lower
CD137 mRNA expression, with increased
carotid IMT and increased incidence of
noncardiac vascular events. This finding
is surprising, since stimulation of CD137
is known to promote atherosclerosis and
increase inflammation in murine models
of atherosclerosis (14,15). Previous stud-
ies have demonstrated higher CD137 ex-
pression in human atherosclerotic tissue
compared with normal arteries, suggest-
ing an association between high CD137
activity and atherosclerotic disease (14).
However, because healthy normal arter-
ies, used as controls in the previous stud-
ies, lack significant inflammatory activity,
the comparison may not translate to the
situation in the present study that com-
pares genotypes in individuals with ei-
ther subclinical or clinical atherosclerosis.
Observations of differences in expres-
sion of immune-regulatory molecules
may be of interest for understanding the
different clinical courses of atheroscle-
rotic disease in males and females
(27,28). It has been reported that genetic
variants of other members of the tumor
necrosis superfamily, for example, OX40
ligand and LIGHT, are associated with
gender differences in risk for disease and
clinical outcome (29–31). The association
of rs2453021 with CD137 expression was
stronger in the set of lymphoblastoid
cells derived from males than from fe-
males. However, in the human cohorts,
the association between rs2453021 and
vascular disease was not consistently dif-
ferent between sexes. Nevertheless, the
results of the present study, including
both the results from cell lines and the
cohorts, indicate that regardless of mech-
anism, potential sex differences may be
important to consider in future studies of
CD137 in atherosclerosis. The mecha-
Table 3. Association of rs2453021 with incident vascular events: model 3.
Hazard ratio (95% CI) n P
Any vascular eventa 1.085 (0.869–1.354) 176 0.472
Cardiac event 0.924 (0.694–1.232) 111 0.592
Noncardiac eventb 1.424 (1.024–1.981) 74 0.036
Cerebrovascular event 1.403 (0.973–2.023) 60 0.070
Peripheral event 1.716 (0.935–3.149) 21 0.081
The minor T allele of rs2453021 was associated with increased risk of incident noncardiac
vascular events. Data collected at the 36-month follow-up of participants of the IMPROVE
cohort were analyzed to explore associations of rs2453021 and incident clinical vascular
events. Cardiac events included MI, sudden cardiac death, angina pectoris and coronary
revascularization; cerebrovascular events included ischemic stroke and transient ischemic
attack; and peripheral events included revascularization of peripheral arteries and new
diagnosis of intermittent claudication (20). Results are from Cox regression with
adjustments according to model 3 (sex, age, genetic background [MDS] and risk factors
for CVD [hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia,
hypertension, diabetes, current smoking, smoking pack-year categories, BMI and CRP]).
Hazard ratios with 95% CIs per rare T allele are given. The number of subjects suffering one
or more vascular events among 3,295 individuals with nonmissing covariates is shown. 
aThe first of a cardiac, cerebrovascular or peripheral events. 
bThe first of a cerebrovascular or peripheral events.
Table 4. Association of rs2453021 and risk
for CAD or MI.
Odds ratio (95% CI) P
All 1.013 (0.933–1.100) 0.757
Women only 1.019 (0.880–1.180) 0.798
Men only 1.011 (0.920–1.113) 0.814
MI 1.028 (0.945–1.119) 0.521
CAD only 1.013 (0.877–1.169) 0.862
The minor T allele of rs2453021 is not
associated with increased risk for CAD or
MI. A total of 13,029 individuals in the
PROCARDIS cohort including WTCCC
controls (5,765 cases and 7,264 controls)
were investigated for association between
rs2453021 and risk for CAD or MI. All results
were adjusted for age, sex, country and
relatedness. The T allele frequency was
0.394.
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nisms underlying these observed sex dif-
ferences are currently unknown, but ge-
netic and epigenetic mechanisms, includ-
ing hormone-induced changes, may be at
play. The functional aspects of these find-
ings need to be addressed in future
mechanistic studies both in vitro and in
vivo.
The present study found an associa-
tion of rs2453021 with noncardiac vascu-
lar events, but not with cardiac events,
suggesting that the distinct vascular sites
may be affected differently. Previous
studies of the TNFSF member OX40 lig-
and found association between genotype
and MI, but not with ischemic stroke,
which may suggest a similarly differen-
tial role for this TNFSF molecule at
unique vascular disease locales (31,32).
Although atherosclerosis underlies both
CAD and carotid plaques, there are sig-
nificant differences in the pathophysiol-
ogy of these manifestations. The anatom-
ical and functional properties, local
rheology and specific function of the ves-
sels differ (6,33,34). In addition, some of
the established risk factors for atheroscle-
rosis may also contribute in a differenti-
ated way to the pathogenesis in unique
vascular beds. For example, hyperten-
sion is a major risk factor for stroke, hy-
percholesterolemia is a major risk factor
for CAD, and smoking and diabetes are
major risk factors for peripheral vascular
disease (34). Also, MI is largely caused
by thrombosis and local lumen occlu-
sion, whereas stroke often is a result of
embolism from ruptured carotid athero-
sclerotic plaques (33,34). The effects of
the interaction between CD137 expres-
sion, vascular bed differences and differ-
ent risk factors are not known, but they
may likely contribute to differences in
local effects of receptor expression on
atherosclerosis development. Of note,
this study does not directly investigate
the role of CD137 activity in the patho-
genesis of human vascular disease and
does not provide conclusive data on its
role in plaque inflammation. Future
studies are warranted to address the cel-
lular and molecular mechanisms behind
these observations.
The surprising association of the
minor allele of rs2450321 with a reduc-
tion of CD137 mRNA expression in lym-
phoblasts and with an increase in risk
for noncardiac vascular events and in-
creased IMT, respectively, may have sev-
eral explanations. For example, CD137 is
known to be constitutively expressed on
human and murine TREG, whereas TEFF
mainly express CD137 upon activation
(11,35). TREG are present at all stages of
atherosclerosis development in both
human and murine atherosclerosis
(8,36). Depletion of TREG leads to in-
creased atherosclerosis in murine disease
models (8,37). Because CD137 is ex-
pressed on regulatory as well as effector
T cells, the TREG/TEFF activity is likely to
affect the result of CD137 activation
(11,16). Although the net effects of
CD137 stimulation in development of
human atherosclerotic disease are cur-
rently unknown, it is tempting to specu-
late that the minor T allele of rs2453021
is associated with a more unfavorable
TEFF/ TREG activity balance, which would
promote inflammation and aggravate
atherosclerosis in the carotid arteries.
Furthermore, in humans, the
CD4+CD28null T-cell population, an aber-
rant subpopulation that lacks the key
costimulatory molecule CD28, expands
with age and is increased in patients
with ACS compared with patients with
stable angina or controls (13). CD137
may substitute for CD28 in
CD4+CD28null T cells and play a role in
costimulation of effector responses
(13,26). It is therefore conceivable that al-
terations in the expression level of
CD137 have effects in patients with high
levels of the disease-associated
CD4+CD28null T cells. Blocking of CD137
in this subset leads to an inhibition of in-
flammatory and cytotoxic functions,
which suggests a role for CD137 in
plaque rupture and ACS (1,2,6,13,38). It
is possible that the decreased expression
of CD137 mRNA associated with
rs2453021 in the present study may play
a role in reducing activation of the
harmful CD4+CD28null T cells and ulti-
mately lead to less plaque inflammation
and less clinical symptoms of CAD. Im-
portantly, the original observation of as-
sociation between the minor T allele and
CD137 expression level was made in
lymphoblastoid cell lines and may not
directly translate into expression in pa-
tients with MI, peripheral vascular dis-
ease or stroke. Bearing this limitation in
mind, we report that the minor T allele
of rs2453021 was found to decrease the
expression of CD137, and additional dis-
ease association studies showed that this
same T allele was associated with in-
creased intima-media thickness and in-
creased risk for noncardiac vascular
events. Other considerations are that
CD137 mRNA levels may not directly
correlate with tissue levels of functional
receptor protein, but the current study
design prevented direct measurements
of relevant protein levels. Potential dif-
ferences in receptor efficacy, turnover
time and ligand availability may also af-
fect CD137 function. Nevertheless, the
observed difference in mRNA level is in-
teresting and warrants further studies of
the functional effects of this finding.
The potential benefit of including im-
aging data on an individual’s atheroscle-
rotic burden in the clinical evaluation of
cardiovascular risk is under debate (39).
Carotid IMT, as measured by high-
 resolution ultrasound, is a widely used
marker of subclinical atherosclerosis.
Previous studies have shown associa-
tions of genotype and IMT (40), and in-
creased IMT has been associated with in-
creased risk of MI and stroke (4,40,41). In
the present study, we chose to use this
established measurement of subclinical
atherosclerosis. In the IMPROVE cohort,
extensive IMT measurements were ac-
quired according to a standardized pro-
tocol to minimize the intra- and interob-
server variability inherent to this method
(4,20). The use of a noninvasive evalua-
tion of subclinical atherosclerosis in sub-
jects free of any clinical manifestation of
atherosclerosis at baseline provides an
opportunity to investigate atherosclerosis
in a wider population, before the onset of
clinical manifestations (4,6,41). In the ini-
tial analysis, association of the rs2453021
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T allele with slower IMT progression
was observed, but this association did
not survive adjustment for established
vascular risk factors and appeared to be
influenced by confounding by diabetes
status. However, after adjustment for
risk factors, these data do show associa-
tion of rs2453021 with increased IMT.
We have previously shown expression
of CD137 in carotid lesions (14), and this
study builds on and expands that find-
ing. The association between the minor
T allele of rs2453021 and increased IMT
in the CCA suggests a role in atheroscle-
rosis build-up in these vessels, possibly
through the relative TREG/TEFF activity.
The current findings suggest a preferen-
tial role of rs2453021, or perhaps CD137
in general, in noncoronary rather than
coronary atherothrombotic events. We
can only speculate that this relates to
differences in etiology of atherothrombo-
sis in different vascular beds. However,
the role of CD137 in coronary plaque
rupture and the presence of CD137 in
coronary artery lesions need further in-
vestigation, as does the influence of the
CD137-expression-level–associated
rs2453021 in ischemic stroke.
CONCLUSION
The minor T allele of rs2453021 was
associated with decreased CD137 mRNA
expression and increased IMT in the
CCA. There was also a significant associ-
ation between the minor T allele of
rs2453021 and increased risk of incident
clinical noncardiac vascular events. In
contrast to the noncardiac vascular
events, no link was found between
rs2453021 alleles and CAD. Our results
indicate a possible role of CD137 in
human CVD and that CD137 genotypes
may have clinical impact. Further studies
are warranted to determine the value of
these new insights into CD137 biology.
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